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1104 The Journal of Thoracic and CardObjective: To examine whether children with univentricular defects have intrinsic
dysfunction in the natriuretic peptide system.
Methods: We compared plasma levels of the fluid-regulating hormone vasopressin
(antidiuretic hormone), aldosterone, atrial natriuretic peptide, and brain natriuretic
peptide in children with congenital univentricular and biventricular defects. We
enrolled 27 patients with univentricular defects and 27 patients with biventricular
cardiac defects. Children who underwent Fontan and Glenn procedures were con-
sidered as patients with univentricular cardiac defects; children who underwent
repair of tetralogy of Fallot or subaortic stenosis were considered as controls with
biventricular defects.
Results: Preoperative plasma atrial natriuretic peptide, brain natriuretic peptide,
antidiuretic hormone, and aldosterone were comparable in both groups. Although
plasma cyclic guanosine monophosphate levels were comparable between groups,
there was a significant correlation between molar concentrations of plasma cyclic
guanosine monophosphate and plasma atrial natriuretic peptide (r 0.42) and brain
natriuretic peptide (r 0.44) in the biventricular group, but not in the univentricular
group (r  0.19 for atrial natriuretic peptide; r  0.13 for brain natriuretic peptide).
All patients had a significant postoperative increase in plasma antidiuretic hormone.
A significant postoperative increase in plasma brain natriuretic peptide was found in
the patients with biventricular, but not univentricular, defects. In contrast, a signif-
icant increase in plasma aldosterone was observed only in the patients with uni-
ventricular defects.
Conclusions: There were distinct differences between univentricular and biventricu-
lar groups in their perioperative plasma fluid-regulating hormone responses. Spe-
cifically, patients with univentricular defects may have abnormal natriuretic peptide
secretion and function. The natriuretic dysfunction may be on the basis of hypo-
plastic ventricular development.
T he natriuretic peptide system has 3 natriuretic peptides, and 2 of thesenatriuretic peptides are cardiac hormones that have been reported to regulatefluid homeostasis.1-4 Atrial natriuretic peptide (ANP) is a 28 –amino acid
peptide hormone derived from a prohormone synthesized and mostly stored in the
atria. It causes diuresis, natriuresis, and vasorelaxation. It inhibits the release and
action of the antidiuretic hormone (ADH) vasopressin and the antinatriuretic hor-
mone aldosterone. B-type natriuretic peptide (BNP) is a 32–amino acid peptide
hormone secreted in the ventricles that also promotes natriuresis and diuresis and
induces vasodilation, with antagonist effects on vasopressin (ADH) and aldoste-
rone.1,3,5 The second-messenger pathway for both of these hormones involves a
cyclic guanosine monophosphate (cGMP)-dependent pathway mediated through
stimulation of the membrane-bound guanylyl cyclase. In addition, ANP may also
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Dtransduce its signal via a cyclic adenosine monophosphate–
dependent pathway mediated through inhibition of adenylyl
cyclase.
Studies in the rat heart indicate that the ventricular con-
tent of ANP messenger RNA is high during the fetal period
and then gradually diminishes until its rapid disappearance
after birth.2 The atrial content of ANP messenger RNA is
low during the fetal period but increases progressively after
birth. Studies of the ontogeny of the ANP hormonal system
in the human heart also revealed the appearance of signif-
icant quantities of ventricular ANP beginning in the early
fetal period that decreased with advancing gestational
age.2,4 It is not known whether this developmental transition
from ventricular to atrial predominance of ANP is disrupted
when cardiac malformation occurs during organogenesis,
particularly in situations involving underdevelopment of
one of the ventricles, such as congenital hypoplastic right or
left ventricles. An increase in plasma ANP has been con-
sistently found in patients with congenital cardiac de-
fects,5-8 and this suggests that the secretion or release (or
both) of the hormone is intact. There is much less informa-
tion regarding the developmental pattern of BNP gene ex-
pression and hormone secretion.
Although plasma natriuretic peptide secretion has been
examined in adults and children after cardiac surgery,9-12
the precise role of natriuretic hormones in the regulation of
fluid balance in the pediatric patient who has had cardiac
surgery has not been well studied. No study has specifically
examined natriuretic hormone receptor/effector signal trans-
duction in the pediatric patient with univentricular cardiac
defects. Children who undergo palliative or reparative pro-
cedures for univentricular defects often have postoperative
complications related to the regulation of fluid homeosta-
sis.13,14 Fontan and Glenn procedures are frequently per-
formed in patients with single ventricles.15-18 Pleural effu-
sion, pericardial effusion, and fluid retention often
complicate the postoperative course of these patients.19,20
Fontan patients often have increased ANP because of many
different factors. Earlier studies have documented that
plasma ADH is correlated with fluid retention in the pres-
ence of increased ANP in these patients, and this is consis-
tent with a defect in ANP cellular action.19 Other investi-
gators have similarly documented increased plasma ADH
and ANP in patients having Glenn procedures.20 Neverthe-
less, no study has examined the change in plasma BNP in
these patients, nor has any study examined the natriuretic
receptor coupling to the guanylyl cyclase enzyme. Tetral-
ogy of Fallot and subaortic stenosis are 2 congenital cardiac
defects that are surgically corrected during early infancy.
Neither of these lesions involves underdevelopment of the
ventricles.
Plasma levels of both ANP and BNP are increased in
patients with congestive heart failure.21-24 Downregulation
The Journal of Thoracicof ANP receptors coupled to guanylyl cyclase, as evidenced
by plateauing plasma levels of cGMP in the presence of
increased plasma ANP levels, has been reported in patients
with severe congestive heart failure.25 Plasma ANP concen-
trations are increased in patients with cyanotic congenital
cardiac defects, even without clinical evidence of failure.26
In addition, plasma ANP and BNP levels have been reported
to be increased in children with congenital cardiac defects
undergoing cardiopulmonary bypass for cardiac sur-
gery.10,27,28 In healthy individuals, plasma ANP far exceeds
plasma BNP.29 In patients with cardiac failure, not only do
plasma ANP and BNP both increase, but ventricular secre-
tion of BNP is also greatly stimulated, so that plasma BNP
is higher than plasma ANP.30
In this study, we studied 2 groups of patients: (1) those
with univentricular defects who were undergoing Fontan or
Glenn procedures and (2) those with biventricular defects
who were undergoing repair of tetralogy of Fallot or sub-
aortic stenosis. We hypothesized that the altered fluid bal-
ance that often complicates the postoperative course after
Fontan and Glenn procedures may be attributable to dys-
function in the natriuretic peptide hormonal system. The
dysfunction could occur at several steps: natriuretic peptide
synthesis, storage, release, receptor coupling, and receptor
signal transduction could be affected alone or in
combination.
Methods
The study was approved by the institutional review board. Two
groups of patients were studied (Table 1):
1. Patients with congenital univentricular cardiac defects:
patients undergoing Fontan or bidirectional Glenn shunt
operations with congenital hypoplastic right heart defects
(tricuspid atresia, single ventricle, Ebstein anomaly, or
other congenital cardiac defects associated with hypoplas-
tic right ventricle) or patients who have had the Norwood
procedure for hypoplastic left heart syndrome.
2. Control patients with congenital cardiac defects but with 2
ventricular chambers: patients undergoing repair of tetral-
ogy of Fallot or subaortic stenosis.
All patients had general endotracheal tube anesthesia with a
standardized anesthetic regimen consisting of fentanyl 25 to 50
g/kg and vecuronium 0.2 mg/kg as the intravenous muscle re-
TABLE 1. Patient data
Variable Univentricular Biventricular
Age (mo) 28.1 28 22.8  24.2
Sex (male/female) 15/12 15/12
Duration of CPB (min) 135.9 75 115.8  49.6
Duration of crossclamp (min) 70.4 46.9 65.6  23.1
Lowest temperature (°C) 25 5.6 25  2.6
CPB, Cardiopulmonary bypass.laxant for induction; 100% oxygen was used in all patients. Each
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Dpatient then received fentanyl 100 g/kg before the initiation of
cardiopulmonary bypass. Sodium nitroprusside was used as the
vasodilator during cardiopulmonary bypass. If indicated, anesthe-
sia was supplemented with isoflurane and midazolam 0.1 to 0.3
mg/kg during and after cardiopulmonary bypass.
Blood samples were collected into chilled tubes containing
aprotinin (a peptidase inhibitor) and isobutylmethylxanthine (a
phosphodiesterase inhibitor) after the induction of anesthesia, be-
fore surgical incision, on postoperative day 1, and on postoperative
day 2 and were maintained on ice. Plasma was then separated and
stored at 70°C. Peptide and cyclic nucleotides were extracted,
Figure 1. Plasma BNP was comparable before surgery in the
univentricular and biventricular patients. A significant increase
in plasma BNP was seen during the first 2 postoperative days in
the biventricular patients on postoperative day (POD) 1 and POD
2. No change in plasma BNP was evident in the univentricular
patients. *P < .05 versus before surgery (PREOP).
Figure 2. Plasma ANP was comparable between univentricular
and biventricular patients (n  27 in each group). No significant
change in plasma ANP was observed during the first 48 hours
after surgery, on postoperative day (POD) 1, or on POD 2. PREOP,
Before surgery.
1106 The Journal of Thoracic and Cardiovascular Surgery ● Maand ANP, BNP, and cGMP were measured with commercially
available radioimmunoassay kits.
One-way analysis of variance was used to determine the change
over time of ANP, BNP, and plasma cGMP for each group.
Pairwise comparisons were performed between different points
and preincision values by the Bonferroni test for ANP, BNP, and
cGMP within groups. Comparisons between groups were made
with nested analysis of variance. Correlation of ANP and/or BNP
with plasma cGMP was assessed by least-squares linear
regression.
Results
The plasma natriuretic peptides ANP and BNP were com-
parable before surgery in children with univentricular (n 
27; ANP, 156.3  30 pg/mL; BNP, 167.5  21.2 pg/mL)
and biventricular (n  27; ANP, 205.9  36 pg/mL; BNP,
178.3  20.7 pg/mL) defects. We determined the perioper-
ative pattern of plasma ANP and BNP to examine the
natriuretic peptide response to cardiac surgery in these
children. In children with biventricular defects, there was a
significant postoperative increase in BNP (Figure 1) and
very little change in plasma ANP (Figure 2). In contrast,
both plasma ANP (Figure 2) and BNP (Figure 1) remained
unchanged during the first 48 hours after the Glenn and
Fontan procedures. It is interesting to note that the aldoste-
rone response was robust after surgery in children with
univentricular defects but was unremarkable in those with
biventricular defects (Figure 3). There was a significant
increase in ADH on postoperative day 1 in children with
both univentricular and biventricular defects (Figure 4).
Plasma cGMP is released in response to stimulation of
membrane-bound natriuretic peptide receptors. Therefore,
Figure 3. Plasma aldosterone was comparable in both groups.
Although biventricular patients showed no change in plasma
aldosterone, univentricular patients showed a significant in-
crease in plasma aldosterone on both postoperative day (POD) 1
and POD 2. *P < .05 versus before surgery (PREOP).plasma cGMP may be considered as a crude surrogate
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correlation of molar concentrations of cGMP and plasma
natriuretic peptide to evaluate receptor/cGMP coupling.
There was a significant correlation between preoperative
plasma cGMP and plasma ANP in the biventricular group (r
 0.42; P  .04), but not in the univentricular group (r 
0.19; P  .33). Similarly, a significant correlation was
found between plasma BNP and cGMP in patients with
biventricular defects (r  0.44; P  .02; Figure 5), but not
in those with univentricular defects (r  0.13; P  .51;
Figure 6). Therefore, there seemed to be an uncoupling of
preoperative natriuretic peptides from the intracellular
cGMP signaling pathway. Moreover, in both groups of
patients, there was no clear relationship between either ANP
or BNP and plasma cGMP after surgery, thus suggesting
that the coupling of the natriuretic peptide receptors to their
signaling cascades was disrupted during the immediate
postoperative period.
Discussion
The main findings of this study were that patients with
univentricular cardiac defects showed evidence of dysfunc-
tion of the BNP system in 2 ways. First, their baseline
plasma ANP and BNP were less well correlated with plasma
cGMP compared with those with biventricular defects. This
is consistent with the idea that natriuretic peptide receptors
are less well coupled to the intracellular signaling pathway
in these patients. Second, plasma BNP in the univentricular
group remained unchanged after surgery, whereas plasma
BNP in those with biventricular defects increased
significantly.
Increased plasma ANP and BNP are reported in patients
with a variety of cardiac diseases.5,7,8,31-33 Specifically,
Figure 4. Biventricular and univentricular patients showed sim-
ilar patterns of plasma ADH during the perioperative period. Both
groups had a significant increase in plasma ADH on postopera-
tive day (POD) 1 that returned to preoperative values by POD 2. *P
< .05 versus before surgery (PREOP).patients with congenital cardiac defects show an increase in
The Journal of Thoracicplasma ANP and BNP.7,8,34 We found plasma ANP and
BNP in both groups of patients to be similar to values that
have been reported in the literature for patients with con-
genital cardiac disease.7,35 It has also been noted that there
is often a greater increase in plasma BNP than in ANP (in
molar concentrations) in cardiac patients.26 In contrast to
noncardiac patients whose plasma ANP is much higher than
plasma BNP, plasma BNP often approaches or is higher
than plasma ANP in cardiac patients.25,36 Consistent with
these earlier reports, we found that both the univentricular
and biventricular groups had comparable plasma ANP and
BNP. More recently, plasma ANP and BNP have been used
as biomarkers of cardiac dysfunction in clinical cardiac
medicine. Plasma BNP is now used as a diagnostic tool and
is used as a marker for the prognosis and evaluation of
therapy in adults with heart failure.5,21,37,38 The recombi-
nant human BNP is now available for therapeutic use in the
Figure 5. Preoperative plasma cGMP significantly correlated
with plasma ANP and plasma BNP in patients with biventricular
defects (P < .05).
Figure 6. Preoperative plasma cGMP did not correlate with either
plasma ANP or plasma BNP in patients with univentricular de-
fects.
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Dtreatment of compensated heart failure because of its doc-
umented beneficial effect to improve cardiac function inde-
pendently of its diuretic effect.38
ANP and BNP are both important in the maintenance of
volume homeostasis through inducing natriuresis, diuresis,
and vasodilation.1,3,39 They also act to inhibit the renin-
angiotensin-aldosterone axis. Another important role played
by the natriuretic peptides is the regulation of cardiac
growth during development.2 This is underscored by the
finding that mice that are genetically engineered to be
devoid of natriuretic peptide receptors have increased heart
weights and increased cardiac expression of both ANP and
BNP.2 The actions of ANP and BNP to inhibit vascular
smooth muscle cell proliferation, to suppress cardiac fibro-
blast growth, and to inhibit cardiomyocyte hypertrophy
have been well documented.2
Univentricular defects are associated with hypoplastic
development of one of the ventricles. Because ANP and
BNP are hormones that are both produced in the ventricles
during embryonic development, we hypothesized that hyp-
oplasia of the ventricle and maldevelopment of the ventri-
cles could lead to a disruption in the ontogeny of the ANP
and BNP system.
Both ANP and BNP bind to cell-surface natriuretic pep-
tide receptors to stimulate the membrane-bound guanylyl
cyclase and to generate the second-messenger cGMP to
exert its biological action.4,39,40 Plasma cGMP, the second
messenger of natriuretic peptide action, has also been shown
to be increased in children with cardiac disease.25,41 Cyclic
GMP can be generated via stimulation of particulate or
cytosolic guanylyl cyclase. Natriuretic peptides are the only
known endogenous ligands that simulate the particulate
form of the guanylyl cyclase enzyme, whereas nitric oxide
stimulates the cytosolic form of the guanylyl cyclase en-
zyme.42,43 Because of the intracellular location of the cyto-
solic guanylyl cyclase enzyme, plasma cGMP reflects the
cellular production of cGMP by the particulate form of the
guanylyl cyclase enzyme in response to natriuretic peptide
stimulation. The correlation between plasma natriuretic
peptides and cGMP could thus be used as a crude estimate
of the coupling of the natriuretic peptide receptors to
their intracellular signaling pathway.25,44 Our results in-
dicate that although the increase of plasma ANP, BNP,
and cGMP was comparable in the univentricular and
biventricular groups, only in the biventricular group was
there a significant linear correlation between plasma ANP
or BNP and plasma cGMP. In contrast, plasma ANP or
BNP was poorly correlated with plasma cGMP in the
univentricular group.
Although we clearly documented that there was a differ-
ence in natriuretic peptides between the univentricular and
biventricular groups, our results by no means establish a
cause and effect relationship between hypoplastic ventricu-
1108 The Journal of Thoracic and Cardiovascular Surgery ● Malar development and abnormal natriuretic peptide function.
However, the clear difference between the univentricular
and biventricular groups in the postoperative change in
plasma BNP is consistent with our hypothesis that ventric-
ular hypoplasia induces a disruption in the ontogeny of the
natriuretic peptide system.
It was entirely predictable that there would be a postop-
erative increase in BNP, as was the case with the biven-
tricular patients, because increases in plasma BNP have
been clearly documented after cardiopulmonary bypass in
adults. However, there was no such increase in plasma BNP
during the postoperative period in patients with univentricu-
lar defects. Studies examining fluid-regulating hormones in
Fontan and Glenn patients have documented increased
plasma ADH and aldosterone during the postoperative pe-
riod.13,19,27,45 Furthermore, the increase in ADH has been
correlated with the development of fluid-retentive states
clinically.19,20 In this study, we found plasma ADH to be
increased in both groups of patients during the postoperative
period. However, the response in BNP and aldosterone was
significantly different between the 2 study groups. In the
patients with biventricular defects, there was a significant
postoperative increase in BNP, but not aldosterone. In con-
trast, in the patients with univentricular defects, there was a
significant increase in plasma aldosterone, but not BNP.
Because BNP is known to inhibit the secretion of aldoste-
rone, the absence of the inhibitory influence of BNP may
account for the significant postoperative increase in aldo-
sterone in the univentricular group.
Persistent postoperative fluid retention, pleural effusion,
pericardial effusion, and ascites frequently complicate the
postoperative course of patients who undergo the Fontan
procedure.19,46,47 Although we did not specifically docu-
ment the fluid status of our patients after surgery, the
persistent increase in ADH and aldosterone with a concom-
itant absent natriuretic peptide response in the univentricu-
lar group might predispose these patients toward a greater
tendency for fluid retention. Our results suggest that the
complications related to fluid retention after univentricular
repair, which have been often attributed to the surgical
procedures, may in fact be due to an inherent defect or
dysfunction of the natriuretic peptide system in patients
with congenital univentricular defects who undergo those
procedures.
Because we demonstrated that plasma cGMP did not
correlate with plasma natriuretic peptides in univentricular
patients, our results suggest that the natriuretic receptor/
effector uncoupling may represent an inherent defect in the
function of the natriuretic peptide system in these patients.
Consequently, one might further speculate that the thera-
peutic actions of exogenously administered BNP could be
attenuated in this group of patients. Future studies specifi-
cally detailing the response to recombinant BNP in this
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Dpopulation will shed light on this issue. Our results indicate
that there was a significant increase in plasma aldosterone
during the postoperative period; this may be a secondary
effect of the abnormal natriuretic response. This suggests
that there might be a role for aldosterone antagonists in the
management of postoperative fluid retention in this patient
population.
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The Thoracic Surgery Foundation for Research and Education
The Thoracic Surgery Foundation for Research and Education (TSFRE) was founded to provide its four
sponsoring societies with a dedicated and common organization for research and education activities within
cardiothoracic surgery. The TSFRE has developed a variety of distinctive, cutting-edge research endeavors,
including clinical research partnerships with the National Heart, Lung, and Blood Institute and the National
Cancer Institute. These partnerships will lead to significant progress in our specialty. In developing these
research programs, TSFRE provides surgeons with dynamic opportunities to extend themselves while benefiting
cardiothoracic surgery and our patients. Research leads to discovery, new techniques and procedures, and
ultimately to dramatic advances to pressing medical and surgical problems.Recognizing that both education and
research create the future of cardiothoracic surgery, the TSFRE has also developed an exciting new education
initiative. Based on the TSFRE Education Committee’s extensive analysis of future needs of cardiothoracic
surgeons, TSFRE is creating three education programs that will support funding of projects in the acquisition of
transdisciplinary skills, patient safety, and simulation training for cardiothoracic surgeons. We are currently
reaching out to industry and major philanthropic organizations to establish funding for these forward looking
programs.As the onset of the income tax season often leads to consideration of various options for the use of
one’s funds, TSFRE asks you to make an annual donation to the Foundation or, if you are already a donor, to
increase the level of your gift. Tax-deductible gifts and pledges that sum to $10,000 will make you a Life Member
of TSFRE. Annual gifts can include securities that have appreciated in value, thereby providing you with
additional tax relief.TSFRE especially asks you to use this time to reflect on building your legacy within the
specialty. Please consider, as an acknowledgment of what cardiothoracic surgery has done for you, by making
a planned gift to TSFRE. Planned giving offers a donor many ways in which to make a sizeable donation without
a cash outlay. The most common planned gift is a charitable bequest to TSFRE through your will after you have
properly insured that your family and other loved ones will be financially secure. Real estate as a planned gift
can be a very practical mechanism. A donor may even give real estate and yet retain the use of the property.
Other forms of planned giving include life insurance and charitable remainder trusts. You might consider
establishing a charitable trust in the name of your family.Once you have made the basic decision that you would
like to support research and education in cardiothoracic surgery, please visit our Web site (www.tsfre.org) and
make a donation online. In considering a planned gift and the options available to you, we urge you to consult
with your financial advisor. TSFRE would also be happy to discuss these and other planned gift options with you.
Please feel free to contact Joe Webber, the Director of Development, at 978-927-8330 or e-mail him at
jwebber@prri.com.y 2005
